About Ran-binding protein 3-like
Ran-binding protein 3-like (RANBP3L) is a protein
from Homo sapiens identified by UniProt accession
Q86VV4, 465 residues long.
MolForge cross-references it against 0 known binders and
32 disease associations.
Target properties
| Protein name | Ran-binding protein 3-like |
| UniProt accession | Q86VV4 |
| Gene | RANBP3L |
| Organism | Homo sapiens |
| Length | 465 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (32)
Diseases linked to this target (Open Targets).
- type 2 diabetes mellitus · score 0.26
- interstitial nephritis · score 0.25
- renal tubule disease · score 0.25
- hypertension · score 0.24
- intraocular pressure measurement · score 0.20
- fat body mass · score 0.16
- reticulocyte count · score 0.12
- reticulocyte measurement · score 0.11
- lean body mass · score 0.09
- appendicular lean mass · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86VV4-F1 | alphafold | PREDICTED | 61.27 | — |
Amino-acid sequence (465 residues)
MTTIPRKGSS HLPGSLHTCK LKLQEDRRQQ EKSVIAQPIF VFEKGEQTFK RPAEDTLYEA AEPECNGFPT KRVRSSSFTF HITDSQSQGV RKNNVFMTSA LVQSSVDIKS AEQGPVKHSK HVIRPAILQL PQARSCAKVR KTFGHKALES CKTKEKTNNK ISEGNSYLLS ENLSRARISV QLSTNQDFLG ATSVGCQPNE DKCSFKSCSS NFVFGENMVE RVLGTQKLTQ PQLENDSYAK EKPFKSIPKF PVNFLSSRTD SIKNTSLIES AAAFSSQPSR KCLLEKIDVI TGEETEHNVL KINCKLFIFN KTTQSWIERG RGTLRLNDTA STDCGTLQSR LIMRNQGSLR LILNSKLWAQ MKIQRANHKN VRITATDLED YSIKIFLIQA SAQDTAYLYA AIHHRLVALQ SFNKQRDVNQ AESLSETAQQ LNCESCDENE DDFIQVTKNG SDPSSWTHRQ SVACS
Explore Ran-binding protein 3-like with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets